Surrozen Inc. (SRZN)
11.25
-0.21 (-1.88%)
At close: Mar 03, 2025, 3:59 PM
10.70
-4.89%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 9.5 |
| Market Cap | 36.56M |
| Revenue (ttm) | 14.24M |
| Net Income (ttm) | -44.74M |
| EPS (ttm) | -16.94 |
| PE Ratio (ttm) | -0.66 |
| Forward PE | -2.67 |
| Analyst | Buy |
| Ask | 11.77 |
| Volume | 2,320 |
| Avg. Volume (20D) | 36,325 |
| Open | 11.25 |
| Previous Close | 11.46 |
| Day's Range | 11.20 - 11.25 |
| 52-Week Range | 6.00 - 18.17 |
| Beta | 0.74 |
About SRZN
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 11, 2021
Employees 42
Stock Exchange NASDAQ
Ticker Symbol SRZN
Website https://www.surrozen.com
Analyst Forecast
According to 2 analyst ratings, the average rating for SRZN stock is "Buy." The 12-month stock price forecast is $38.5, which is an increase of 242.22% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
+7.29%
Surozen shares are trading higher after HC Wainwri...
Unlock content with
Pro Subscription
1 month ago
+19.44%
Surrozen shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy.
